TrialCNS oncology2022

A first-in-human Phase I trial of the oral p-STAT3 inhibitor WP1066 in patients with recurrent malignant glioma.

John de Groot et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.